Table 1.

Previous studies of anti-CD16 × IL-15 TriKEs with different specificity in various cancer models

Antibody format	Ligand specificity	Tumor type	Target model	References
scFv-IL-scFv	CD33	Hematologic malignancy	AML	[7]
scFv-IL-scFv	EpCAM	Carcinomas	Carcinomas	[13]
scFv-IL-scFv	CD133	Solid tumor and hematologic malignancy	Colorectal carcinoma and Burkitt lymphoma	[14]
scFv-IL-scFv	CD19	Hematologic malignancy	B-CLL CD19+ tumor	[15]
scFv-IL-scFv	CD19	Hematologic malignancy	CD19+ tumor	[16]
sdAb-IL-scFv	B7-H3	Solid tumor	Ovarian cancer	[20]
sdAb-IL-scFv	CD33	Hematologic malignancy	AML	[25]
sdAb-IL-scFv	HER2	Solid tumor	Ovarian cancer	[26]
sdAb-IL-scFv	CLEC12A	Hematologic malignancy	AML	[9]
sdAb-IL-scFv	TEM8	Solid tumor	NSCLC	[10]
sdAb-IL-scFv	Mesothelin	Solid tumor	NSCLC	[27]
sdAb-IL-scFv	BCMA	Hematologic malignancy	MM	[11]

EpCAM: epithelial cell adhesion molecule; AML: acute myeloid leukemia; B-CLL: B cell chronic lymphocytic leukemia; NSCLC: non-small cell lung cancer; MM: multiple myeloma; HER2: human epidermal growth factor receptor 2; CLEC12A: C-type lectin domain family 12 member A; B7-H3: B7 homolog 3; BCMA: B-cell maturation antigen; TEM8: tumor endothelial marker 8